Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model - role of tumor stroma cells by Leithner, K. (Katharina) et al.
Leithner et al. BMC Cancer 2014, 14:40
http://www.biomedcentral.com/1471-2407/14/40RESEARCH ARTICLE Open AccessHypoxia increases membrane
metallo-endopeptidase expression in a novel
lung cancer ex vivo model – role of tumor
stroma cells
Katharina Leithner1, Christoph Wohlkoenig1, Elvira Stacher2, Jörg Lindenmann3, Nicole A Hofmann4,5, Birgit Gallé6,
Christian Guelly6, Franz Quehenberger7, Philipp Stiegler8, Freyja-Maria Smolle-Jüttner3, Sjaak Philipsen9,
Helmut H Popper2, Andelko Hrzenjak1,11, Andrea Olschewski10,11 and Horst Olschewski1*Abstract
Background: Hypoxia-induced genes are potential targets in cancer therapy. Responses to hypoxia have been
extensively studied in vitro, however, they may differ in vivo due to the specific tumor microenvironment. In this
study gene expression profiles were obtained from fresh human lung cancer tissue fragments cultured ex vivo
under different oxygen concentrations in order to study responses to hypoxia in a model that mimics human lung
cancer in vivo.
Methods: Non-small cell lung cancer (NSCLC) fragments from altogether 70 patients were maintained ex vivo in
normoxia or hypoxia in short-term culture. Viability, apoptosis rates and tissue hypoxia were assessed. Gene
expression profiles were studied using Affymetrix GeneChip 1.0 ST microarrays.
Results: Apoptosis rates were comparable in normoxia and hypoxia despite different oxygenation levels,
suggesting adaptation of tumor cells to hypoxia. Gene expression profiles in hypoxic compared to normoxic
fragments largely overlapped with published hypoxia-signatures. While most of these genes were up-regulated by
hypoxia also in NSCLC cell lines, membrane metallo-endopeptidase (MME, neprilysin, CD10) expression was not
increased in hypoxia in NSCLC cell lines, but in carcinoma-associated fibroblasts isolated from non-small cell lung
cancers. High MME expression was significantly associated with poor overall survival in 342 NSCLC patients in a
meta-analysis of published microarray datasets.
Conclusions: The novel ex vivo model allowed for the first time to analyze hypoxia-regulated gene expression in
preserved human lung cancer tissue. Gene expression profiles in human hypoxic lung cancer tissue overlapped with
hypoxia-signatures from cancer cell lines, however, the elastase MME was identified as a novel hypoxia-induced
gene in lung cancer. Due to the lack of hypoxia effects on MME expression in NSCLC cell lines in contrast to
carcinoma-associated fibroblasts, a direct up-regulation of stroma fibroblast MME expression under hypoxia might
contribute to enhanced aggressiveness of hypoxic cancers.
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Survival following diagnosis of non-small cell lung can-
cer (NSCLC) is poor despite therapy [1]. Hypoxia is typ-
ically present in solid tumors like lung cancer and is
known to enhance tumor progression and therapy resist-
ance [2]. The effects of hypoxia are largely mediated by
the hypoxia-inducible factors (HIFs) HIF-1α [3,4] and
HIF-2α [5]. HIFs induce the expression of many differ-
ent proteins that are involved in key functions of cancer
cells, including cell survival, metabolic reprogramming,
angiogenesis, invasion, and metastasis. Under normoxic
conditions, HIFs are rapidly degraded, while under hypoxia
they are stabilized [3,4]. In addition to oxygen-dependent
regulation, HIFs can be up-regulated by other mecha-
nisms, e.g. growth factor induced pathways [3,4]. The
biological response of tumors to hypoxia is influenced
by the interplay of neoplastic cancer cells and the sur-
rounding stroma cells, e.g. cancer-associated fibroblasts
(CAFs) [6]. Ex vivo human cancer models based on the
short-term culture of small tumor fragments or slices
are suitable to study tumor responses within the nat-
ural in situ microenvironment, comprising a close con-
tact between tumor cells and the accompanying stroma
cells. Such models have been used e.g. for the study
of drug effects in lung cancer [7] and other cancers [8,9].
Here we used a human ex vivo lung cancer model involv-
ing culture of fresh tumor fragments in a hypoxic at-
mosphere to mimic in vivo tumor hypoxia and performed
a comparative expression profiling study. We found
that hypoxia led to overexpression of a stem-cell marker
with elastase activity, membrane metallo-endopeptidase
(MME), in tumor fragments, which was attributable to
carcinoma-associated fibroblasts, not the neoplastic can-
cer cells.Methods
Lung cancer fragments
Tumor tissue samples from 70 consecutive patients with
NSCLC who were referred for surgical resection to the
Division of Thoracic and Hyperbaric Surgery, Medical
University of Graz, from May 2007 to May 2013, were
included in the study. Patients with pre-operative chemo-
therapy were excluded from the study. Surgical specimens
were dissected into small fragments using a razor blade
and fragments were incubated in 35 mm Petri dishes
(up to ten fragments per well) in 2 ml of DMEM/F-12
growth medium (Gibco, Carlsbad, CA) containing 10%
fetal calf serum (Biowest Ltd, Ringmer, UK), 2 mM
L-glutamine (Gibco), 100 U/ml penicillin, and 100 μg/ml
streptomycin (Gibco). The study protocol was approved
by the ethics review board of the Medical University of
Graz. Signed informed consent was obtained from all
patients prior to surgery.Cells
The human NSCLC cell lines A549 and A427 were pur-
chased from Cell Lines Service (Eppelheim, Germany)
and cultured in DMEM/F-12 medium containing the sup-
plements described above. The human NSCLC cell lines
NCI-H23, NCI-H358, NCI-H1299, and NCI-H441 were
purchased from American Type Culture Collection (ATCC,
Manassas, VA) and cultured in RPMI (Gibco), supple-
mented with 10% fetal calf serum (Biowest) and antibiotics.
Carcinoma-associated fibroblasts (CAFs) were isolated
from three fresh NSCLC samples as described [10] and
cultured in DMEM supplemented with 10% fetal calf
serum (Biowest) and antibiotics. CAFs were identified
to be positive for vimentin and negative for cytokera-
tin using immunofluorescence. The purity of the cells
was 97-99%. Human lung fibroblasts were cultured
from donor lungs that could not be used for transplant-
ation as previously described [11].
Hypoxic culture
Fragments were cultured for three days at 37°C in ambi-
ent (21%) oxygen or 1% oxygen in the automated Xvivo
System G300CL (BioSpherix, Lacona, NY). NSCLC cells
or fibroblasts were plated into cell culture flasks at
13,000/cm2 and let attach, thereafter cells were cultured
for three days in ambient oxygen or 1% oxygen as de-
scribed above. Exposure to oxygen was controlled through-
out the experiments in the hypoxic workstation.
MTT assay
The MTT assay (Chemicon, Billerica, MA) was per-
formed on cultured fragments according to the manu-
facturer’s instructions. Briefly fragments were incubated
in the MTT substrate solution for one hour and forma-
zan was dissolved in isopropanol. After dissolving the
formazan 100 μL of sample was analyzed on a colorimet-
ric microplate reader at 570 nm. A549 cells were used as
a positive control.
Pimonidazole assay
The assay (Hypoxyprobe™, HPI, Burlington, MA) was
performed essentially according to the manufacturer’s
instructions. Fragments were incubated for one or three
days in hypoxia or normoxia. Thereafter fragments were
treated with 100 μM pimonidazole HCl (HPI) in hypoxia
in the closed Xvivo hypoxic working chamber (BioSpherix)
or in normoxia and incubated for one hour, fixed and
paraffin embedded. Bound pimonidazole was visualized
using mouse monoclonal pimonidazole antibody (1:50 di-
lution, HPI).
RNA extraction and cDNA synthesis
Total RNA was extracted using the Qiagen RNeasy Mini
kit (Qiagen, Hilden, Germany) and DNase digestion
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RNA integrity was assessed using the Agilent 2100 Bioa-
nalyzer and the Agilent RNA 6000 Nano Kit (Agilent,
Palo Alto, CA). All samples exhibited a RIN (RNA Integrity
Number) >5. Samples with RIN > 8 were eligible for micro-
array analysis. Total RNA (1 μg) was reverse transcribed
using the RevertAid H Minus First Strand cDNA synthesis
kit (Fermentas, Burlington, Canada).
Quantitative real-time PCR
For single gene quantitative polymerase chain reactions
(PCR) the 7900 Real-Time PCR System (Applied Biosys-
tems, Foster City, CA) was used. Gene expression assays
(TaqMan® Gene Expression Assays, Applied Biosystems)
suitable for this system were used for the detection of car-
bonic anhydrase IX, PPP1R3C, MME, KCTD11, FAM115C,
and hexokinase 2. ACTB (ß-actin) was used as a refer-
ence gene. Primer data are indicated in Additional file 1:
Table S2. The PCR was performed in 10 μl reactions con-
taining cDNA (equal to 2.5 ng or 12.5 ng total RNA),
1× TaqMan® Gene Expression Mastermix (Applied Biosys-
tems) and 1× TaqMan® Gene Expression Assay (Applied
Biosystems). The mean threshold cycle (Ct) number of
triplicate runs was used for data analysis. ΔCt was calcu-
lated by subtracting the Ct number of the gene of interest
from that of the reference gene β-actin (ACTB). For calcu-
lation of differences between two groups, ΔCt-values of
the control group (normoxia) were substracted from ΔCt-
values of the treated group (hypoxia).
Expression profiling
The microarray analysis was performed using GeneChip
Human Gene 1.0 ST Arrays (Affymetrix, Santa Clara,
CA). Manufacturer’s instructions were followed for the
hybridization, washing, and scanning steps. Pre-labelled
spike-in controls, unlabelled spike controls, and back-
ground probes were included in the analysis. All the
microarray data are available at Gene Expression Omni-
bus (GEO; http://www.ncbi.nlm.nih.gov/geo/; accession
number GSE30979).
Processing of microarray data
Statistical analysis of the microarray data was performed
using Partek Genomic Suite Software (Partek, St. Louis,
MO). RMA (Robust Multi Chip Analysis) background
correction of raw microarray data and normalization of
expression values were performed using Partek Genomic
Suite Software (Partek). Fold-changes of expression values
were calculated as the ratio of the mean RMA corrected
expression value in the hypoxic group to the normoxic
group. Fold-change values <1 were converted to the nega-
tive of the inverse ratio. Hypoxic and normoxic samples
were compared using the paired Student’s t-test. The false
discovery rate (FDR) was set to 5% to correct for multipletesting. In the case of subgroup analyses, the threshold
was set to P<0.005. A gene was considered modulated
when at least one of the corresponding probe sets showed
significantly different expression levels after correction for
multiple testing with a minimal two-fold change.
Meta-analysis of lung cancer transcriptome studies
Expression values for the genes of interest were obtained
from four eligible lung cancer datasets published at Gene
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/
geo/). Details on data processing and patient characteris-
tics are reported at GEO and in the cited literature. Details
on data retrieval are indicated in Additional file 1.
Statistical analysis
Meta-analysis of the effect of MME on patient survival
after surgery was performed with a proportional haz-
ards model with Gaussian random effects [12,13] using
the package coxme 2.1-3 of R 2.13.2 statistical software
(www.r-project.org). For details see Additional file 1. All
other data were compiled and analyzed with the SPSS
software package, version 18.0 (Chicago, IL). Group differ-
ences were calculated with the paired Student’s t-test,
one-sample Student’s t-test, Mann–Whitney-U test, or
Wilcoxon signed rank test as applicable. P-values smaller
than 0.05 were considered significant.
Results
Apoptosis and hypoxia markers in NSCLC fragments
NSCLC tissue was fragmented immediately after surgery.
Fragments were maintained in culture medium for three
days, both in ambient oxygen or hypoxia (1% O2). The lar-
gest diameter measured from paraffin sections (n = 430) was
1.19 mm (median, range 0.2 mm to 2.9 mm), the smallest
diameter was 0.8 mm (median, range 0.2 mm to 2.2 mm).
There was no significant difference between the size of frag-
ments cultured in normoxia or hypoxia (P = 0.972). The
histomorphology of cultured NSCLC fragments resembled
the growth patterns usually found in freshly resected
NSCLC tissue. Cancer cell nests were found in close prox-
imity to stroma-rich regions with only scattered tumor
cells. Tumor cells were found in the vast majority of cul-
tured fragments, large necroses were rare. The MTT assay
was used to determine, whether cells in cultured frag-
ments were metabolically active, as an indirect qualitative
indicator of cell viability. All fragments tested (n = 15 hyp-
oxic and 15 normoxic fragments from three different pa-
tients) showed a positive MTT reaction. Apoptosis rates
of tumor cells were investigated using immunohistochem-
ical staining for cleaved caspase 3 (Figure 1A). No sig-
nificant difference was found between apoptosis rates in
normoxic and hypoxic fragments (Figure 1A).
HIF-1α and HIF-2α immunohistochemistry was per-
formed in NSCLC fragments cultured for three days under
Figure 1 (See legend on next page.)
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Figure 1 Apoptosis and hypoxia markers in normoxic and hypoxic ex vivo cultured lung cancer fragments. (A) Apoptosis is not increased
in hypoxic ex vivo cultured NSCLC fragments. Representative images of cleaved caspase 3 staining for the assessment of apoptosis are shown: a
hypoxic adenocarcinoma fragment cultured for three days in hypoxia without visible apoptosis and a fragment treated with 32 μM cisplatin as
positive control. Right, apoptosis rates were determined by counting cleaved caspase 3 positive tumor cells in a blinded manner. Lines indicate
mean +/− SEM. Groups were compared with the Mann–Whitney-U test. (B) HIF-1α and HIF-2α immunoreactivity in NSCLC fragments after three
days of incubation in hypoxia or normoxia. Arrowhead: stroma cell, arrow: tumor cell. HIFs were evaluated in tumor cells and stroma cells
semi-quantitatively in a blinded manner. Groups were compared with the paired Student’s t-test. (C) Pimonidazole staining indicating hypoxia in
fragments cultured for one or three days in hypoxia or normoxia. Representative images are shown. All sections were counterstained with hematoxylin.
(D) Carbonic anhydrase IX (CA IX) mRNA in hypoxic vs. normoxic NSCLC fragments (n = 14 patients). No difference in expression gives a value of zero.
Significance was calculated with the single group Student’s t-test. Results are mean +/− SEM. NOX, normoxia; HOX, hypoxia.
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predominantly in the nucleus, while HIF-2α was found in
the cytoplasm. Both, cytoplasmic and nuclear localization
of HIF-1α and HIF-2α, have been reported [14,15]. Hyp-
oxic fragments displayed more pronounced staining for
HIF-1α than normoxic fragments, though the difference
was significant only in stroma cells, not in tumor cells
(Figure 1B). For HIF-2α no difference between fragments
cultured in hypoxia or normoxia was found, neither in
tumor cells, nor in stroma cells (Figure 1B). Next we
assessed the presence of hypoxia in cultured fragments
using pimonidazole. Figure 1C shows examples of NSCLC
fragments cultured in normoxia or hypoxia for one and
three days. Pimonidazole was bound almost to the entire
hypoxic fragments, while only focal pimonidazole binding
occurred in normoxic fragments, obviously due to di-
minished oxygen concentrations in central fragment
areas. In several hypoxic fragments some cells showed
higher pimonidazole binding than others (Figure 1C),
which might be caused by a different content of redox en-
zymes (J. Raleigh, Hypoxyprobe Inc. and UNC School of
Medicine, Chapel Hill, North Carolina, USA, personal
communication) or due to other cell-related causes, such
as differences in pimonidazole uptake or pH [16]. Expres-
sion of the HIF-1α target carbonic anhydrase IX (CA IX),
which was shown to be linked to hypoxia in NSCLCs
in vivo [17], was analyzed by quantitative PCR. CA IX
mRNA levels were significantly higher in hypoxic frag-
ments compared to normoxic fragments (Figure 1D).
Taken together, NSCLC fragments remained viable for the
duration of the experiments and hypoxia markers were in-
creased under hypoxic treatment.
Gene regulation by hypoxia in NSCLC fragments
In order to identify hypoxia-responsive genes, normoxic
and hypoxic fragments derived from ten patients were
subjected to expression profiling. A total of 107 genes
were significantly regulated by hypoxia; 28 genes were up-
regulated (Table 1) and 79 genes were down-regulated
(Additional file 2: Table S3). Hypoxia expression patterns
differed between histological subtypes (Figure 2A). Four
genes were significantly regulated in the same direction(up-regulated) in both subtypes with a minimal two-
fold change: PPP1R3C (protein phosphatase 1 regulatory
subunit 3C), KCTD11 (potassium channel tetrameri-
sation domain containing 11), FAM115C (family with
sequence similarity 115 member C), and membrane
metallo-endopeptidase (MME, CD10, neutral endo-
peptidase, neprilysin) (Figure 2A). The GO annotations
(www.geneontology.org) for the gene products are as follows:
PPP1R3C, regulation of glycogen biosynthesis; KCTD11,
regulation of cell proliferation; and MME, proteolysis.
The gene product of FAM115C has unknown function.
Hypoxia-regulation of the four overlapping hypoxia genes
and of the known hypoxia-responsive gene hexokinase 2
(HK2) was confirmed using real-time PCR in normoxic
and hypoxic fragments from an independent validation set
(n = 8, Figure 2B).
Interestingly, the overall impact of hypoxia on gene
expression was lower than the impact of histology or
inter-patient variability (Additional file 3: Figure S1).
Normoxic and hypoxic fragments derived from each pa-
tient clustered together significantly in 9 of 10 patients
in pvclust analysis (Additional file 3: Figure S1). Both
clusters on the top of the hierarchy were significant in
pvclust analysis. One cluster contained four squamous cell
carcinomas, the other cluster contained all adenocarcin-
omas and one squamous cell carcinoma (Additional file 3:
Figure S1).
MME immunohistochemistry
In order to determine the cell types responsible for
MME expression in our model we performed immuno-
histochemical staining in fresh NSCLC specimens from
12 patients. MME-positive neoplastic tumor cells were
found in 80% and scattered MME-positive stroma cells
were found in 54% of fresh cancer specimens. Up to 30%
of stroma cells were MME positive in cultured frag-
ments, indicating generally increased MME expression
in tumor stroma cells under stress conditions (Figure 3B).
Using this technique, no difference in MME staining in
normoxia or hypoxia was found. However, since immuno-
histochemistry is a semiquantitative method, only large
differences in expression levels can be detected. Next,
Table 1 Genes up-regulated by hypoxia
Gene symbol Gene name P Fold-change
PPP1R3C Protein phosphatase 1, regulatory (inhibitor) subunit 3C 7,6E-07 2,5
HK2 Hexokinase 2 3,4E-06 2,1
GBE1 Glucan (1,4-alpha-), branching enzyme 1 3,9E-06 2,3
KDM3A Lysine (K)-specific demethylase 3A 5,6E-06 2,0
KCTD11 Potassium channel tetramerisation domain containing 11 6,3E-06 2,2
FAM115C Family with sequence similarity 115, member C 1,1E-05 2,3
BNIP3 BCL2/adenovirus E1B 19 kDa interacting protein 3 3,6E-05 2,1
DNAJB9 DnaJ (Hsp40) homolog, subfamily B, member 9 4,6E-05 2,4
MME Membrane metallo-endopeptidase 7,3E-05 2,5
IL8 Interleukin 8 8,3E-05 2,3
DTNA Dystrobrevin, alpha 9,0E-05 2,1
C7orf68 Chromosome 7 open reading frame 68 9,5E-05 2,4
LOX Lysyl oxidase 1,2E-04 2,7
HSPA13 Heat shock protein 70 kDa family, member 13 1,7E-04 2,2
LRRC49 Leucine rich repeat containing 49 1,9E-04 2,0
STC2 Stanniocalcin 2 2,2E-04 2,2
TREM1 Triggering receptor expressed on myeloid cells 1 2,5E-04 2,3
CDR1 Cerebellar degeneration-related protein 1 2,5E-04 2,2
ADM Adrenomedullin 2,5E-04 2,2
NUCB2 Nucleobindin 2 3,6E-04 2,4
TSPYL2 TSPY-like 2 5,8E-04 2,0
DDIT3 DNA-damage-inducible transcript 3 6,3E-04 2,5
C1orf129 Chromosome 1 open reading frame 129 8,2E-04 3,4
FICD FIC domain containing 1,0E-03 2,4
FABP3 Fatty acid binding protein 3 1,3E-03 2,0
ABI3BP ABI family, member 3 (NESH) binding protein 1,3E-03 2,0
NOG Noggin 1,4E-03 2,1
SEC11C SEC11 homolog C 4,0E-03 2,2
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tients were stained for MME and HIF-1α in order to
analyze, whether the expression of both is linked in vivo.
Similar to the first series MME staining was found in
tumor cells in 21/30 samples (70%) and in stroma cells in
10/30 samples (33.3%; 5 to 20% of stroma cells were
MME positive). In 8/30 patients (26.7%), HIF-1α positivity
was found in tumor cells. In 2/30 (6.7%) patients also
stroma cells were HIF-1α positive. In a sample with very
high stroma and tumor cell HIF-1α expression, HIF-1α
and MME staining overlapped in stroma cells, but not
in tumor cells (Figure 3A, images A-F). On the other
hand in another patient with MME stroma staining
no HIF-1α was found (Figure 3A, images G and H).
In tumor cells MME and HIF-1α staining were not
strongly related. Together this indicated to us that in
some patients hypoxia may be linked to MME expres-
sion in the tumor stroma.Expression of hypoxia-regulated genes in NSCLC cells and
carcinoma-associated fibroblasts (CAFs)
We further analyzed the expression of MME under hypoxia
in both, NSCLC cell lines and fibroblasts, which are the pre-
dominant cell type in lung cancer stroma, using quantitative
PCR. PPP1R3C, KCTD11, FAM115C, and HK2, a well-
known hypoxia-regulated gene, were up-regulated by hyp-
oxia in a panel of NSCLC cell lines to variable degrees, while
MME mRNA showed no increase in expression under hyp-
oxia in any of the cell lines (Figure 3C). On the contrary in
carcinoma-associated fibroblasts (CAFs) from NSCLC and,
to a lesser extent, in primary lung fibroblasts MME mRNA
was significantly up-regulated by hypoxia (Figure 3D).
MME expression is an adverse prognostic factor in lung
adenocarcinoma patients
Next, we examined whether expression of the four hyp-
oxia genes was associated with survival in patients with
Figure 2 Top 20 hypoxia-regulated genes according to P-values and validation of microarray results using quantitative PCR. (A) Only
significantly regulated genes with a minimum fold-change of 2 are included. The analysis was performed for all samples (n = 20 patients) or for
adenocarcinoma (n = 10 patients) and squamous cell carcinoma (n = 10 patients) separately. Overlapping genes, regulated in the same direction
in both histological subtypes are highlighted. (B) Confirmation of the up-regulation of overlapping hypoxia-regulated genes in hypoxic and
normoxic fragments derived from NSCLC surgical specimens from four patients by quantitative PCR. Results are shown as mean +/−SEM. No
difference in expression gives a value of zero. Significance was calculated with one-sample Student’s t-test. HK2, hexokinase 2; MME, membrane
metallo-endopeptidase; KCTD11, potassium channel tetramerisation domain containing 11; PPP1R3C, protein phosphatase 1 regulatory subunit
3C; FAM115C, family with sequence similarity 115 member C. *P < 0.05, **P < 0.01.
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in our patient cohort, we used large published micro-
array datasets containing gene expression data linked to
clinical and prognostic information in NSCLC patients.
The Gene Expression Omnibus (GEO; http://www.ncbi.
nlm.nih.gov/geo/) is one of the largest microarray data-
bases. A search for GEO datasets/series using the search
criteria „lung cancer 50:500[Number of Samples]” yielded
84 results (status June 2011). Of these 84 datasets/series,
68 contained expression profiling data. Four of these
series included expression data of a minimal number
of 50 NSCLC patients treated by surgery with linked
information on survival, GSE11969 [18], GSE13213 [19],
GSE14814 [20], and GSE19188 [21]. Altogether 342 pa-
tients were included in the meta-analysis.
Of the four overlapping hypoxia genes MME was the
only prognostic factor for overall survival (P = 0.00057)
in a multivariate analysis with pathological tumor stage as
stratification variable. The interaction between MME and
histology (adenocarcinoma vs. non-adenocarcinoma) was
statistically significant (P = 0.027). Thus survival analyses
were performed in adenocarcinoma patients and non-
adenocarcinoma patients separately (Figure 4). High ex-
pression of MME was significantly associated with poorer
survival in adenocarcinoma patients of series GSE13213
(P = 0.00025) and series GSE14814 (P = 0.029), and in thecombined cohort including 182 patients (P = 0.000012,
Figure 4A,B). In series GSE13213 and in the combined
cohort, but not in series GSE14814, the association be-
tween MME and survival was significant even after
Bonferroni correction for multiple testing for all genes/
probe sets in all the studies. In the combined cohort of
adenocarcinoma patients the hazard ratio (HR) for death
in the high MME group was 3.0 (95% CI 1.83- 4.90;
Figure 4A). In non-adenocarcinoma patients the risk for
death was not different in the high MME group compared
with the low MME group (HR = 0.93, 95% CI 0.35- 2.4,
P = 0.496; Figure 4A,B).Discussion
Identifying hypoxia-regulated genes may promote under-
standing of the molecular response to hypoxic stress in
cancers. Changes in gene expression in hypoxic cancer
cells have been studied extensively in vitro. However,
hypoxia-responses in vivo may differ from the in vitro
situation due to the complex tumor microenvironment.
In fact, hypoxia activates tumor promoting stroma cells
and HIF-1α has been identified as the major driver of
tumor-stroma “co-evolution” [22]. Here we studied hypoxia-
induced gene expression experimentally in human cancer
tissue in its preserved 3D-structure. In this fragment
Figure 3 Expression of MME in NSCLC samples, NSCLC cell lines, and fibroblasts. (A) MME and HIF-1α were stained in consecutive sections
of fresh NSCLC. Representative areas from a sample with high HIF-1α staining in tumor (arrow) and stroma cells (arrowhead) are shown (images A-F).
While MME positive stroma cells were found predominantly in HIF-1α positive areas, no association of HIF-1α and MME was found in tumor cells. Note
the intensely MME positive stroma cells (asterix) surrounding an islet of tumor cells, which were MME negative. Images G and H show a sample from a
different patient. In this patient MME staining in stroma cells was apparently unrelated to HIF-1α. Scale bar: 200 μm. (B) Immunohistochemistry for
MME in normoxic and hypoxic fragments from a single patient. (C) NSCLC cells were cultured in hypoxia (1% oxygen) or ambient oxygen for three
days and mRNA levels of hexokinase 2 and of the four overlapping hypoxia genes were analyzed. Expression levels in hypoxia relative to normoxia
are shown. Results are mean +/− SEM from three independent experiments. (D) Human lung fibroblasts from three different donors and
carcinoma-associated fibroblasts (CAFs) isolated from NSCLC from three different patients were cultured in hypoxia (1% oxygen) or ambient oxygen
for three days and MME mRNA levels were analyzed. Results are mean +/− SEM from n = 5 to 7 independent experiments. (C and D) Groups were
compared with one-sample Student’s t-test. HK2, hexokinase 2; MME, membrane metallo-endopeptidase; KCTD11, potassium channel tetramerisation
domain containing 11; PPP1R3C, protein phosphatase 1 regulatory subunit 3C; FAM115C, family with sequence similarity 115 member C; nox,
normoxia; hox, hypoxia. *P < 0.05, **P < 0.01, ***P < 0.001.
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and mimics the in vivo situation.
The model has several advantages compared to in vitro
cancer cell lines. The tumor cells remain in contact with
their original tumor microenvironment (stroma cells,
extracellular matrix), the 3D-morphology is preserved, andinter-patient variability is taken into account by using ma-
terial derived from different patients. The major limitation
of our study is that the exact oxygen concentration could
only be controlled on the surface of the fragments. Inside
the tumor fragments there are supposed to be oxygen gra-
dients, depending on the size and composition of the tissue
high MME
expression
high MME
expression
low MME
expression
low MME
expression
BA
Adenocarcinoma
Non-adenocarcinoma
GSE13213
GSE14814
GSE19188
Overall
P       n
0.00025    117
0.029      27
0.22      38
0.000012    128
Adenocarcinoma
P       n
0.71      57
0.59      62
0.26      41
0.54    160
GSE11969
GSE14814
GSE19188
Overall
Non-adenocarcinoma
Figure 4 MME expression is associated with poor prognosis in lung adenocarcinoma patients treated with surgery. (A) Based on the
expression of MME in microarrays from tumor specimens, NSCLC patients from publically available GEO microarray series were stratified into
patients with high MME expression (the highest quartile) versus low MME expression (the remaining three quartiles). The association between
MME expression and overall survival was calculated within the GEO series, and in cohorts derived by combining the different GEO series.
All analyses were performed in a multivariate manner with pathological tumor stage as stratification variable. Adenocarcinoma and
non-adenocarcinoma patients from each study were analyzed separately. Study GSE13213 contained only adenocarcinoma patients. From study
GSE11969 only the non-adenocarcinoma patients were included due to potential overlap with patients from GSE13213, who were operated at the
same centre. Results are displayed as hazard ratio for death in the high MME group versus the low MME group +/− 95% confidence interval.
(B) Kaplan-Meier plot of overall survival in adenocarcinoma patients (n = 182) and non-adenocarcinoma patients (n = 160) from the combined
cohort dichotomized according to the expression levels of MME.
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did not differ in our study. In fact, using pimonidazole
staining, fragments cultured in hypoxia were found to be
entirely hypoxic, while only a core of hypoxia was found
in fragments cultured in normoxia. In addition to pimoni-
dazole, also other major hypoxia-markers were signifi-
cantly increased in the hypoxic fragments, such as HIF-1α
and CA IX. However, HIF-2α, which is known to be stabi-
lized by hypoxia similarly to HIF-1α, was expressed only
at low levels, both in normoxia and hypoxia, and was not
elevated in hypoxic fragments. Different co-activators
and different kinetics of activation under hypoxia [23]
might play a role. This indicates that the difference in
oxygen concentration was preserved despite the expected
oxygen gradients inside the fragments. Furthermore the
oxygen decline is supposed to occur in both, normoxic
and hypoxic fragments. Thus our approach is feasible to
study differential gene expression under high and low oxy-
gen concentrations.Apoptosis rates were comparable in NSCLC fragments
cultured in 1% O2 or normoxia for three days. This agrees
with our previous study where we showed that hypoxia-
induced adaptation and cisplatin-resistance are reversible
in lung cancer cells and occur without hypoxia-induced
cell death and selection [24]. In an attempt to identify
common hypoxia-regulated genes, Ortiz-Barahona et al.
[25] identified 17 genes consistently up-regulated by hyp-
oxia, hypoxia-mimetics, or HIF-1α using a meta-analysis
of expression data from 16 GEO datasets. Of these 17,
mostly well-known hypoxia-regulated genes, 65% appear
among the significantly regulated genes in our study (after
correction for multiple testing). When we compared a
hypoxia signature found to be prognostically relevant in
many cancers (the “hypoxia metagene” [26]) with our hyp-
oxia profile, we also found a considerable overlap. Ap-
proximately half of the top-ranked hypoxia-induced genes
with prognostic relevance identified by Buffa et al. [26]
were significantly up-regulated by hypoxia in our study.
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in both adenocarcinoma and squamous cell carcinoma
fragments in our setting. We confirmed the differential
expression of the four overlapping hypoxia genes under
hypoxia in an independent validation set using quantitative
PCR (qPCR). Also the well-established hypoxia-responsive
gene HK2, which phosphorylates glucose and thus contrib-
utes to the glycolytic flux in cancer cells, was significantly
up-regulated by hypoxia in the fragments, both in the
microarray analysis and by qPCR.
The four hypoxia-genes identified in our study have
been found to be up-regulated by hypoxia in several
microarray studies, however these findings were not vali-
dated e.g. by qPCR [27-32]. To the best of our knowledge,
validated data on hypoxia-regulation of the four hypoxia-
regulated genes exist for PPP1R3C (up-regulated in MCF-7
breast cancer cells) [33] and on MME, which was shown
to be up-regulated in primary rat astrocytes [34] and
down-regulated in pulmonary artery smooth muscle cells
[35], human neuroblastoma cells [34], rat neurons [34],
and mouse neurons [36]. Cobalt chloride, a hypoxia mi-
metic, was shown to reduce MME expression in prostate
cancer cell lines [37], and human umbilical vein endothe-
lial cells [37]. In addition, exposure of rats and mice to a
hypoxic atmosphere led to down-regulation of MME ex-
pression [38,39].
In our study we found MME localized to neoplastic
tumor cells, but also to stroma cells in fresh NSCLC tis-
sue, which is in line with published data [40,41]. The
observed up-regulation of MME under hypoxia in NSCLC
fragments might thus be attributable to tumor cells
or stroma cells, or both. While the hypoxic regulation
of KCTD11, FAM115C, PPP1R3C and HK2 was also
observed to a variable degree in a panel of NSCLC cell
lines cultured as a monolayer, MME was not regulated by
hypoxia in the cell lines in our study. Fibroblasts are the
predominant cell type in lung cancer stroma [42]. When
we studied MME mRNA in CAFs we found a significant
induction by hypoxia. A similar effect was found in nor-
mal lung fibroblasts, however to a lesser extent. The exact
mechanism of MME regulation by hypoxia in fibroblasts
remains to be elucidated. The proximal promoter regions
of the different MME splice variants have been shown to
harbour binding sites for the transcription factors Sp1,
PEA3 and PU.1 [43]. PEA3 (also known as E1AF and
ETV4) is a member of the Ets-family of transcription fac-
tors. PEA3 was shown enhance cancer metastasis [44]. Re-
cently, PEA3 has been shown to interact with HIF-1α
[45]. This might at least partially be responsible for the
observed effect of hypoxia on MME expression.
MME, which is identical to common acute leukemia
antigen (CALLA), is a 90–110 kDa zinc binding cell sur-
face peptidase, which cleaves small peptides, such as
atrial natriuretic peptide, substance P, endothelin-1, andbombesin (for review see [46,47]). It also possesses elas-
tase activity [48]. MME is a membrane-bound protein,
however, as was recently shown, MME can be released
to the microenvironment of cells in exosomes [49].
MME is expressed in a variety of non-malignant and
malignant tissues (for review see [46,47]) including lung
cancer [40,50-52]. In small-cell lung carcinoma (SCLC)
cells, bombesin-like peptides, substrates for MME, are
autocrine growth factors. Cleaving these peptides by re-
combinant MME has been shown to inhibit SCLC cell
proliferation [53,54]. In NSCLC cells, recombinant MME
inhibited tumor cell proliferation in vitro, but only at very
high concentrations and after long exposure [54]. On the
contrary, MME inhibitors have been found to decrease
cell proliferation in the airway wall in response to cigarette
smoke in rats [55]. While the role of MME in neoplastic
tumor cells is still unclear, several reports suggest that
stroma cell MME expression plays a role in tumor
progression. MME-positive stroma cells, including mesen-
chymal stem cells and fibroblasts, have been shown to
promote tumor aggressiveness and metastasis [56,57].
Elastin is degraded by MME [48], which might facilitate
tumor and/or stroma cell invasion.
In order to analyze, whether levels of the common
hypoxia-genes identified in our study are associated with
overall survival in NSCLC patients we used all eligible
studies deposited in one of the largest microarray de-
positories, the GEO database. We were able to show that
MME expression is a highly significant, independent ad-
verse prognostic factor in surgically treated lung adenocar-
cinoma patients in multivariate analysis involving tumor
stage and MME status. No association was found in the
subgroup of non-adenocarcinoma patients. The reason for
the different results in the histological subgroups is un-
known, however, lung adenocarcinomas have been shown
to possess more elastin than squamous cell carcinomas
[58]. Since the largest study with 116 adenocarcinoma
patients (GSE13213) contained only adenocarcinomas, a
study-bias cannot be excluded.
To the best of our knowledge, three other studies ex-
amined the association of MME expression and survival
in lung cancer [40,41,51]. All studies are immunohisto-
chemical studies. In a study by Kristiansen et al. [51] in
114 NSCLC patients no association of MME immuno-
staining and survival was found. Only neoplastic cancer
cells were evaluated in that study (G. Kristiansen, per-
sonal communication). In a recent study by Ono et al.
[41] on 142 stage I squamous cell lung carcinoma pa-
tients MME expression was examined in tumor cells and
stroma cells separately. Patients with low MME expres-
sion in stroma or in tumor cells survived slightly longer,
but the differences were not significant. In a study by
Gurel et al. [40] MME expression was studied in tumor
cells and stroma cells in 66 patients with NSCLC using
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subgroup high tumor cell and stroma cell MME expres-
sion were both associated with poor overall survival. In
non-squamous cell NSCLC (35 patients, adenocarcin-
oma, large cell carcinoma, sarcomatoid carcinoma, and
mixed types) the opposite association was found. No
stroma cell MME expression was found in that subgroup
[40]. The low number of patients may make the inter-
pretation of these results difficult.
All of these studies were immunohistochemical studies,
in contrast to our MME mRNA based survival analysis.
Since MME may be excreted in exosomes [49], which has
been shown e.g. for mesenchymal stem cells [59], the
question arises, whether MME was excreted and then lost
during conventional tissue fixation and immunohisto-
chemistry. With immunohistochemistry thus the extent of
MME expression in cancer tissue may be underestimated.
This is supported by the fact that CAFs isolated from all
three NSCLCs expressed MME mRNA in our study, while
in the studies mentioned above high MME staining in
stroma cells was found only in 11% to 19% of cases. This
underestimation may partly explain the lack of association
between MME expression and worse prognosis in the
mentioned studies, as opposed to our mRNA based study.
Additional studies examined the expression of MME
in combination with other factors and survival. In the
study by Tokuhara et al. [50] 132 NSCLC patients were
grouped according to their tumor MME mRNA and
aminopeptidase N mRNA expression. Patients assigned
to the group with high MME and low aminopeptidase N
mRNA showed significantly improved survival. No ana-
lysis on MME expression alone was performed. Tumor
tissue samples were selected to contain primarily cancer
cells in that study. In a study by Navab et al. [10] MME
was among a subset of eleven genes identified to be up-
regulated in cancer associated fibroblasts, forming a
prognostic gene-expression signature in NSCLC.
Conclusions
The novel ex vivo model allowed for the first time to
analyze hypoxia-regulated gene expression in preserved
human lung cancer tissue. The study shows that gene
expression profiles in human hypoxic lung cancer tissue
overlap with hypoxia-signatures from cancer cell lines,
however, MME was identified as a novel hypoxia-induced
gene in lung cancer. Despite the advantages of ex vivo
tissue culture, cell monolayers still appear to be the
method of choice to study mechanisms of adaptation of
individual cell types to hypoxia, since the oxygen concen-
tration can be controlled only on the surface of such three-
dimensional structures. Thus we analyzed expression of
the hypoxia-regulated genes identified in the NSCLC frag-
ments in different NSCLC cell lines and primary CAFs iso-
lated from NSCLC tissue. We show that MME expressionis up-regulated by hypoxia in CAFs, not in NSCLC
cells. High global levels of MME mRNA in NSCLC tissue
were shown in our study to predict poor survival. A direct
effect of hypoxia on stromal fibroblast MME expression
might thus contribute to enhanced aggressiveness of hyp-
oxic cancers.
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